CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is highly variable, suggesting that a fixed dosage and time scheduling might be not optimal. We aimed to investigate whether B cell repopulation kinetics influences clinical and radiological outcomes and whether...

Full description

Bibliographic Details
Main Authors: Gianmarco Abbadessa, Giuseppina Miele, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Elisabetta Signoriello, Doriana Landi, Chiara Bosa, Marco Vercellino, Antonio De Martino, Rosanna Missione, Maddalena Sparaco, Luigi Lavorgna, Giacomo Lus, Simona Bonavita
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:International Journal of Environmental Research and Public Health
Subjects:
multiple sclerosis
ocrelizumab
schedule
B cell
CD20
CD19
Online Access:https://www.mdpi.com/1660-4601/18/15/8163

Internet

https://www.mdpi.com/1660-4601/18/15/8163

Similar Items